Elanco Animal Health Incorporated Overview
Pro stress-test →Elanco is a global leader in animal health providing innovation solutions to improve animal health and wellbeing. The company innovates, develops, manufactures, and markets products for pets and farm animals worldwide, serving veterinarians, farmers, and pet owners through an extensive portfolio of pharmaceuticals, vaccines, and biologics.
Strategic Profile
Pro stress-test →Elanco is the third-largest animal health company in the world. The company's Innovation, Portfolio and Productivity (IPP) strategy is designed to guide the company's transformation to a sustainable growth company, delivering consistent mid-single digit organic constant currency revenue growth and adjusted EBITDA margin expansion. Elanco has 10+ major innovation projects with blockbuster potential in development, expecting approvals for 5-6 major differentiated assets from this pipeline between 2026 and 2031, representing an unprobabilized potential peak sales value of more than $2 billion.
Competitive Landscape
Pro stress-test →Elanco ranks as the third-largest animal health company in the world. Primary competitors include Zoetis (leading position in animal health), Boehringer Ingelheim, and Merck Animal Health. Elanco competes through its blockbuster portfolio including Seresto, Credelio, and Interceptor Plus, with differentiation emerging from its monoclonal antibody and immunotherapy platforms.
Industry Context
Elanco Animal Health Incorporated operates in Pharmaceutical/Animal Health.
Key facts
Founded: 1954 · Headquarters: Greenfield, Indiana, US